Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Key points
- Microbiome key to health and disease
- Altered microbiome: C. difficile infection
- Altered microbiome: inflammatory bowel disease
- Altered microbiome: liver disease
- Microbiome therapies
- Interest is growing
- Microbiome therapies restore function
- Example 1: fecal microbiota transplant
- Example 1: FMT for recurrent C. difficile infection
- Example 2: bacteriophage in alcohol hepatitis
- Example 3: rifaximin for hepatic encephalopathy
- Considerations: traditional drug development challenges
- Considerations: unique challenges
- Considerations: logistical issues
- Considerations: regulatory environment
- Considerations: patient selection
- Considerations: primary outcome
- Considerations: placebo effect
- Considerations: assess engraftment
- Considerations: trial design
- Considerations: pre-existing microbiome interaction
- Considerations: safety endpoints
- Safety event
- Future: personalized microbiome therapy
- Key points
- Thank you for listening
Topics Covered
- Fecal microbiota transplant
- Dysbiosis
- Recurrent Clostridium difficile infection
- Inflammatory bowel disease
- Liver disease
- Bacteriophages in alcohol hepatitis treatment
- Hepatic encephalopathy
- Rifaximin
- Considerations for microbiome therapeutic development
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Bloom, P. (2023, March 30). Microbiome therapies to treat gastrointestinal diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/LVOS3190.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Patricia Bloom has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Dr. Patricia Bloom.
I am an Assistant Professor
at the University of Michigan.
Today I'll be talking
with you about
Microbiome therapies to treat
gastrointestinal diseases.
0:16
The key points I want to
address today are that
the microbiome is altered
in many gastrointestinal
diseases and
microbiome therapies may restore
healthy microbiome
function there for
treating some of those
gastrointestinal diseases.
There are many considerations in
the development and testing
of microbiome therapies,
which we'll review today.
The future of this
field points to
personalized microbiome
therapies tailored
to the individual, disease
and microbiome state.
0:56
The microbiome
here is defined as
the indigenous
microbial communities
and the host environment
they inhabit.
The microbiome is
able to influence
many different organ
systems in the body.
As such, it is key to
health as well as disease.
The microbiome does
many things, for
example, produces enzymes.
It is central to
many different
metabolic functions
including carbohydrate,
protein and lipid metabolism.
The microbiome can prevent
pathogen colonization,
influences barrier function,
manufacturers small molecules
with systemic effects,
and can have a central role
in modulating the immune system.
Because of these myriad
effects of the microbiome,
it is key to health and disease.